ESMO E-Learning: Understanding the Role in Clinical Practice of Biomarkers in Advanced NSCLC
- To define the best treatment of metastatic NSCLC with EGFR Mutations in first-line, maintenance and second-line
- To define the role of uncommon EGFR mutations
- To define the mechanisms for EGFR-TKI resistance and how to overcome acquired resistance
|Title||Duration||Content||CME Points||CME Test|
|Understanding the Role in Clinical Practice of Biomarkers in Advanced NSCLC||26 min.||37 slides||1||Take Test|
This E-learning module represents a serious update of a previously released ESMO E-Learning teaching material in the rapidly evolving field of incorporating biomarkers in patients with advanced non–small cell lung cancer (NSCLC). The first module was released two years ago by the same author and the current update, which can actually be considered a totally new presentation, evaluates the molecular mechanisms underpinning responses in patients with activating mutations in the EGFR tyrosine kinase (TK) domain, the role of uncommon EGFR mutations, and how to overcome resistance. Epidermal growth factor (EGF) pathway inhibition is the established option in the first-line, maintenance and second-line treatment in patients with metastatic NSCLC presented with EGFR Mutations and the ultimate goal of this module is to define what the best treatment currently is.
While the first module outlined how EGFR should be incorporated at all into clinical decision making, and elaborated on techniques clinicians should be aware of EGFR mutation analysis, this updated module highlights different mutations in the EGFR Gene and sensitivity to EGFR TKI according to the presence of different mutations. Furthermore, it provides an excellent overview of studies of EGFR-TKIs, and EGFR-TKI vs. chemotherapy in EGFR mutated NSCLC.
The module further discusses if the presence of K-Ras mutations in NSCLC affects clinical outcomes with EGFR-targeted therapy. It covers mechanisms responsible for EGFR-TKI resistance, approaches that include new drugs, and whether they are active against mutations and strategies currently under investigation. With regards to information on treatment that oncologists have acquired and patients are likely to benefit from, this is resulting in the development of improved future strategies.
The author has reported to own EGFR FISH Patent and to be a consultant for Roche, AstraZeneca, Lilly and Pfizer.